J.P. Morgan Notebook, Jan. 12: Lilly, Amgen, Shire, Takeda And Drug Pricing
This article was originally published in The Pink Sheet Daily
Daily round-up of news and notes from the 2016 J.P. Morgan Healthcare Conference in San Francisco.
You may also be interested in...
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.
Pfizer was heavily invested in immuno-oncology combinations five years ago, but following setbacks, the pipeline has shifted considerably, shaped partly by the acquisition of Array.
Newly published data and results presented at ESMO for Amgen’s sotorasib (AMG 510) show relatively long-lasting responses and progression-free survival in lung cancer.